Kyverna Therapeutics (KYTX) Gains from Investment Securities (2023 - 2026)
Kyverna Therapeutics posted quarterly Gains from Investment Securities of $428182.0 for Q1 2026, down 37.74% year-on-year from $687679.0 in Q1 2025, and down 49.03% on a QoQ basis from $840000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Gains from Investment Securities data on file, last reported at $428182.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 37.74% year-over-year to $428182.0; the trailing twelve-month figure through Mar 2026 stood at $428182.0 (down 37.74% YoY), and the FY2025 full-year result was $9.3 million, up 22.84% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $428182.0, down from $840000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $9.9 million in Q2 2025 and bottomed at $5000.0 in Q2 2024.
- The 4-year median for Gains from Investment Securities is $428182.0 (2026), against an average of $1.7 million.
- The widest annual swing landed in 2024, when Gains from Investment Securities sank 97.33%; it then soared 198678.78% in 2025.
- A 4-year view of Gains from Investment Securities shows it stood at $581000.0 in 2023, then slumped by 48.36% to $300000.0 in 2024, then surged by 180.0% to $840000.0 in 2025, then sank by 49.03% to $428182.0 in 2026.
- The last three Gains from Investment Securities figures came in at $428182.0 (Q1 2026), $840000.0 (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 428,182.00 |
| Mar 31, 2026 | 428,182.00 |
| Dec 31, 2025 | 840,000.00 |
| Dec 31, 2025 | 840,000.00 |
| Sep 30, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | 9.94 Mn |
| Jun 30, 2025 | 9.94 Mn |
| Mar 31, 2025 | 687,679.00 |
| Mar 31, 2025 | 687,679.00 |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 4.23 Mn |
| Mar 31, 2024 | 4.23 Mn |
| Dec 31, 2023 | 581,000.00 |
| Dec 31, 2023 | 581,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 187,000.00 |
| Jun 30, 2023 | 187,000.00 |
| Mar 31, 2023 | 168,000.00 |
| Mar 31, 2023 | 168,000.00 |